Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Shahrooz Eshaghian · SciRah

Researcher profile · Semantic Scholar

Shahrooz Eshaghian

Share profile

Shahrooz Eshaghian — researcher profile on SciRah

h-index: 11
Works: 46
Citations: 439

Most-cited papers

Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
S. Stampfer, Marissa-Skye Goldwater, Scott Jew, S. Bujarski +14 more
2021Leukemia85 citations Open access
Semantic Scholar
Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
J. Berenson, Jacqueline Hilger, O. Yellin, R. Dichmann +9 more
2014Leukemia66 citations Open access
Semantic Scholar
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types
C. Rolfo, A. Drilon, D. Hong, C. McCoach +21 more
2021British Journal of Cancer35 citations Open access
Semantic Scholar
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
J. Berenson, Jennifer Q. To, T. Spektor, D. Martinez +11 more
2020Clinical Cancer Research31 citations Open access
Semantic Scholar
Epstein–Barr Virus-Associated Hemophagocytic Lymphohistiocytosis in Los Angeles County
T. Kelesidis, R. Humphries, D. Terashita, Shahrooz Eshaghian +5 more
2012Journal of Medical Virology27 citations Open access
Semantic Scholar
Multiple myeloma: improved outcomes with new therapeutic approaches
Shahrooz Eshaghian, J. Berenson
2012Current Opinion in Supportive and Palliative Care19 citations
Semantic Scholar
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
A. Berenson, S. Vardanyan, Michael David, J. Wang +10 more
2017Annals of Hematology18 citations
Semantic Scholar
A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
J. Berenson, L. Stampleman, A. Bessudo, P. Rosen +7 more
201214 citations
Semantic Scholar
Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination
Samuel D. Stampfer, Marissa-Skye Goldwater, S. Bujarski, B. Regidor +6 more
2021Clinical Infection in Practice13 citations Open access
Semantic Scholar
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma
A. Cohen, T. Spektor, L. Stampleman, A. Bessudo +10 more
2018British Journal of Haematology13 citations Open access
Semantic Scholar
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial
J. Hilger, L. Klein, A. Bessudo, P. Rosen +4 more
201312 citations
Semantic Scholar
Replacement of ixazomib for relapsed/refractory multiple myeloma patients refractory to a bortezomib or carfilzomib-containing combination therapy.
J. Berenson, A. Cohen, Tanya M. Spektor, J. Bitran +13 more
201711 citations
Semantic Scholar
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients
J. Berenson, Clara Kim, S. Bujarski, Jennifer Q. To +11 more
2022Hematological Oncology10 citations
Semantic Scholar
Ruxolitinib and methylprednisolone for treatment of patients with relapsed/refractory multiple myeloma
J. Berenson, D. Martinez, Tahmineh Safaie, R. Boccia +12 more
2022British Journal of Haematology9 citations
Semantic Scholar
Clinical Outcomes and Serum B-Cell Maturation Antigen Levels in a Real-World Unselected Population of Newly Diagnosed Multiple Myeloma Patients
Scott Jew, S. Bujarski, B. Regidor, Marsiye Emamy-Sadr +5 more
2023Targeted oncology7 citations
Semantic Scholar
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia
H. Byun, Shahrooz Eshaghian, Dou-Er Dan, J. Trent +4 more
2017Open Medicine7 citations Open access
Semantic Scholar
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic
A. Berenson, S. Vardanyan, Michael David, J. Wang +10 more
2017Annals of Hematology6 citations
Semantic Scholar
A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM).
J. Hilger, J. Berenson, L. Klein, A. Bessudo +6 more
20135 citations
Semantic Scholar
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
David Yashar, T. Spektor, D. Martinez, Matthew Ghermezi +7 more
2021Leukemia and Lymphoma4 citations
Semantic Scholar
A phase 1 trial of ruxolitinib, lenalidomide, and methylprednisolone for relapsed/refractory multiple myeloma patients.
J. Berenson, Jennifer Q. To, T. Spektor, Carley Turner +8 more
20184 citations
Semantic Scholar
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
D. Daniely, Eli Forouzan, T. Spektor, A. Cohen +11 more
2022Experimental Hematology3 citations Open access
Semantic Scholar
Efficacy and safety of replacing lenalidomide with pomalidomide for patients with multiple myeloma refractory to a lenalidomide-containing combination regimen.
Jonathan Afari, T. Spektor, Carley Turner, A. Cohen +12 more
2022Experimental Hematology3 citations Open access
Semantic Scholar
Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab
D. Yashar, B. Regidor, Scott Jew, S. Bujarski +6 more
2021Blood3 citations Open access
Semantic Scholar
Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa).
G. Sonpavde, R. Nagy, N. Agarwal, T. Gourdin +10 more
20163 citations
Semantic Scholar
DNA Methylation profiling of chronic myelogenous leukemia in relationship to genomic translocation
H. Byun, Shahrooz Eshaghian, Dou-Er Dan, J. Trent +4 more
20133 citations Open access
Semantic Scholar
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
J. Berenson, J. Hilger, R. Dichmann, D. Patel-Donnelly +9 more
20133 citations
Semantic Scholar
Glomerular hemophagocytic macrophages in a patient with proteinuria and clinical and laboratory features of hemophagocytic lymphohistiocytosis (HLH)
Ling Cao, W. Wallace, Shahrooz Eshaghian, Yuliya Linhares +1 more
2011International journal of hematology3 citations
Semantic Scholar
Loss of anti‐spike antibodies following mRNA vaccination for COVID‐19 among patients with multiple myeloma
S. Stampfer, S. Bujarski, Marissa-Skye Goldwater, Scott Jew +9 more
2023Cancer Reports2 citations Open access
Semantic Scholar
Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
J. Berenson, N. Silagan, Jennifer Q. To, T. Spektor +11 more
20202 citations Open access
Semantic Scholar
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/ Refractory Multiple Myeloma Patients
J. Berenson, D. Martinez, T. Spektor, A. Sanchez +7 more
2019Clinical Lymphoma, Myeloma & Leukemia2 citations
Semantic Scholar
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment
Aleksandra Vidisheva, J. Wang, T. Spektor, J. Bitran +13 more
2017Supportive Care in Cancer2 citations
Semantic Scholar
A Phase 1/2 Study of Carfilzomib As a Replacement for Bortezomib for Multiple Myeloma (MM) Patients (pts) Refractory to a Bortezomib-Containing Combination Regimen
J. Berenson, J. Hilger, R. Dichmann, D. Patel-Donnelly +8 more
20122 citations
Semantic Scholar
Acute Dapsone-Induced Methemoglobinemia in a 24-Year-Old Woman with Ulcerative Colitis
R. Brar, S. Eshaghian, Shahrooz Eshaghian, P. Miles
20072 citations
Semantic Scholar
DNA Methylation Analysis of 807 Genes in Chronic Myeloid Leukemia and Acute Promyelocytic Leukemia.
H. Byun, Shahrooz Eshaghian, Jia-Yi Jiang, S. Choi +4 more
20072 citations
Semantic Scholar
Outcomes for unselected, newly diagnosed multiple myeloma patients
Jonathan Moore, Sarah Mettias, Jamie Cheung, R. Swift +4 more
2025Haematologica1 citations Open access
Semantic Scholar
A Phase I Trial Evaluating the Addition of Lenalidomide to Patients with Relapsed/Refractory Multiple Myeloma Progressing on Ruxolitinib and Methylprednisolone
J. Berenson, A. Limón, Stephanie Rice, Tahmineh Safaie +15 more
2024Targeted oncology1 citations
Semantic Scholar
A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone
J. Berenson, A. Limón, Stephanie Rice, Tahmineh Safaie +14 more
2023Blood1 citations Open access
Semantic Scholar
Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma
J. Berenson, D. Martinez, Tahmineh Safaie, N. Silagan +12 more
2021Blood1 citations Open access
Semantic Scholar
A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)
J. Berenson, Jennifer Q. To, T. Spektor, D. Martinez +15 more
2019Blood1 citations
Semantic Scholar
A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).
J. Berenson, L. Klein, P. Rosen, T. Woliver +4 more
20141 citations
Semantic Scholar
A case of ALK-associated non-small-cell lung cancer with evidence of omental metastasis 6 years after initial presentation
S. Kulkarni, F. Kabbinavar, Shahrooz Eshaghian
20131 citations
Semantic Scholar
Methylation Profiling of Three Homogenous Cancers: Chronic Myelogenous Leukemia (CML), Acute Promyelocytic Leukemia (APL) and Gastrointestinal Stromal Tumors (GIST).
H. Byun, Shahrooz Eshaghian, Jia-Yi Jiang, S. Choi +7 more
20061 citations
Semantic Scholar
A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM).
J. Berenson, Jennifer Q. To, T. Spektor, D. Martinez +14 more
2019Journal of Clinical Oncology0 citations
Semantic Scholar
A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients
J. Berenson, Tobi Jennifer, T. Spektor, Carley Turner +10 more
2018Blood0 citations
Semantic Scholar
Analysis of efficacy and safety of POM as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma pts refractory to a lenalidomide-containing combination regimen.
J. Berenson, A. Cohen, T. Spektor, A. Lashkari +12 more
20170 citations
Semantic Scholar
Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).
J. Berenson, L. Stampleman, A. Bessudo, P. Rosen +7 more
20150 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Swift×35
Invite
R. Swift — researcher profile on SciRah
J. Berenson×32
Invite
J. Berenson — researcher profile on SciRah
R. Vescio×25
Invite
R. Vescio — researcher profile on SciRah
T. Spektor×18
Invite
T. Spektor — researcher profile on SciRah

×18

Invite

B. Eades — researcher profile on SciRah

Invite

A. Bessudo — researcher profile on SciRah

Invite

S. Lim — researcher profile on SciRah

Invite

Y. Nassir — researcher profile on SciRah

Gary Schwartz×14

Invite

Gary Schwartz — researcher profile on SciRah

L. Stampleman×12

Invite

L. Stampleman — researcher profile on SciRah

Invite

S. Bujarski — researcher profile on SciRah

Invite

D. Martinez — researcher profile on SciRah